Docking, synthesis and NDM-1 inhibitory activity of some novel cinnamic acid derivatives
Amrita Parle and Tejpal Arora
A series of cinnamic acid derivatives (TA1–TA12) were docked, synthesized and tested for NDM-1 inhibitor activity. Azetreonam anitibiotic is taken as standard for docking and NDM inhibitory activity as azetreonam is the trial antibiotic used to treat the resistant infections caused by NDM-1 producing bacteria. This study found that out of 12 synthesized cinnamic acid derivatives, two compounds TA7 and TA9 show better activity than the standard. Results further revealed that compound TA8 shows equal activity as that of the standard. During the docking studies, compounds TA7 and TA9 have shown better binding affinity to NDM-1 protein while compound TA8 shows equal binding affinity to the standard antibiotic Azetreonam. Thus we can say that our docking results are in concurrence with the NDM-1 inhibitory activity.
How to cite this article:
Amrita Parle, Tejpal Arora. Docking, synthesis and NDM-1 inhibitory activity of some novel cinnamic acid derivatives. Pharma Innovation 2017;6(6):119-123.